Literature DB >> 17203162

Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray.

Sherry X Yang1, Stephen M Hewitt, Seth M Steinberg, David J Liewehr, Sandra M Swain.   

Abstract

The mRNA cap-binding protein, eukaryotic initiation factor 4E (eIF4E), is a rate-limiting factor of cap-dependent translation initiation. When elevated, eIF4E greatly facilitates translation of a selected spectrum of mRNAs coding for proteins critical to angiogenesis and growth such as vascular endothelial growth factor (VEGF) and cyclin D1. Expression levels of eIF4E, VEGF, and cyclin D1 were examined in multi-tumor tissue microarray by immunohistochemistry and analyzed quantitatively. eIF4E, VEGF and cyclin D1 protein were elevated in tumors of the breast (62, 78, or 40%), colon (72, 77, or 12%), glioblastoma multiforme (48, 68, or 52%), lymphoma (66, 74, or 38%), melanoma (59, 73, or 58%), NSCLC (81, 82, or 29%), ovary (50, 39, or 13%), and prostate (78, 97, or 21%), respectively. eIF4E levels were strongly correlated with VEGF and cyclin D1 in melanoma (Spearman's r=0.97 and 0.77; all P<0.0001); moderately in tumors of the breast (r=0.55 and 0.41; all P<0.0005), colon (0.63 and 0.56; all P<0.0001), lung (0.53 and 0.53; all P<0.005), lymphoma (0.50 and 0.61; all P<0.0005), prostate (0.46 and 0.54; all P<0.005), or ovary (0.56 and 0.46; all P<0.005); and weakly in tumors of glioblastoma multiforme (r=0.20 and 0.31; all P>0.15). The significant association of eIF4E with VEGF and cyclin D1 in multiple tumors supports a role for eIF4E in translational regulation of proteins related to angiogenesis and growth.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17203162

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  25 in total

1.  eIF4E is an adverse prognostic marker of melanoma patient survival by increasing melanoma cell invasion.

Authors:  Shahram Khosravi; Kevin J Tam; Gholamreza S Ardekani; Magdalena Martinka; Kevin J McElwee; Christopher J Ong
Journal:  J Invest Dermatol       Date:  2015-01-06       Impact factor: 8.551

Review 2.  Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

Authors:  Katherine L B Borden; Biljana Culjkovic-Kraljacic
Journal:  Leuk Lymphoma       Date:  2010-10

3.  Structure-activity relationship study of 4EGI-1, small molecule eIF4E/eIF4G protein-protein interaction inhibitors.

Authors:  Khuloud Takrouri; Ting Chen; Evangelos Papadopoulos; Rupam Sahoo; Eihab Kabha; Han Chen; Sonia Cantel; Gerhard Wagner; Jose A Halperin; Bertal H Aktas; Michael Chorev
Journal:  Eur J Med Chem       Date:  2014-03-13       Impact factor: 6.514

4.  Post-transcriptional regulation in cancer progression : Microenvironmental control of alternative splicing and translation.

Authors:  Michael Jewer; Scott D Findlay; Lynne-Marie Postovit
Journal:  J Cell Commun Signal       Date:  2012-10-09       Impact factor: 5.782

Review 5.  The biological and therapeutic relevance of mRNA translation in cancer.

Authors:  Sarah P Blagden; Anne E Willis
Journal:  Nat Rev Clin Oncol       Date:  2011-03-01       Impact factor: 66.675

6.  Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer.

Authors:  Yikun Li; Songqing Fan; Junghui Koo; Ping Yue; Zhuo Georgia Chen; Taofeek K Owonikoko; Suresh S Ramalingam; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Biol Ther       Date:  2012-03-01       Impact factor: 4.742

7.  Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer.

Authors:  Akihiko Yoshizawa; Junya Fukuoka; Shigeki Shimizu; Konstantin Shilo; Teri J Franks; Stephen M Hewitt; Takeshi Fujii; Carlos Cordon-Cardo; Jin Jen; William D Travis
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

8.  Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma.

Authors:  Sabrina Marozin; Enrico N De Toni; Antonia Rizzani; Jennifer Altomonte; Alexandra Junger; Günter Schneider; Wolfgang E Thasler; Nobuyuki Kato; Roland M Schmid; Oliver Ebert
Journal:  PLoS One       Date:  2010-06-07       Impact factor: 3.240

9.  The role of CCND1 alterations during the progression of cutaneous malignant melanoma.

Authors:  Laura Vízkeleti; Szilvia Ecsedi; Zsuzsa Rákosy; Adrienn Orosz; Viktória Lázár; Gabriella Emri; Viktória Koroknai; Tímea Kiss; Róza Ádány; Margit Balázs
Journal:  Tumour Biol       Date:  2012-09-23

10.  Tissue microarray analysis of eIF4E and its downstream effector proteins in human breast cancer.

Authors:  Heather E Kleiner; Prasad Krishnan; Jesse Tubbs; Mark Smith; Carol Meschonat; Runhua Shi; Mary Lowery-Nordberg; Patrick Adegboyega; Marcia Unger; James Cardelli; Quyen Chu; J Michael Mathis; John Clifford; Arrigo De Benedetti; Benjamin D L Li
Journal:  J Exp Clin Cancer Res       Date:  2009-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.